Table 5 Calculated values for the Combination Index as a growth inhibitory effect of combination treatment with Herceptin® and 5-FU in gastric cancer cell lines
YBC-2 | Combination Index value | Parameter (μM) | ||||
|---|---|---|---|---|---|---|
Drug | ED50 | ED75 | ED90 | Dm | m | r |
5-FU | Â | Â | Â | 752.04 | 0.27 | 0.94 |
HER | Â | Â | Â | 1201.02 | 0.32 | 0.91 |
5-FU + HER | 8060.81 | 1620.97 | 325.97 | 285.29 | 0.45 | 1 |
Diagnosis combined effect | Antagonism | Antagonism | Antagonism | Â | Â | Â |
YBC-3 | Combination Index value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
5-FU | Â | Â | Â | 4.739 | 0.279 | 0.920 |
HER | Â | Â | Â | 46.063 | 0.623 | 0.970 |
5-FU + HER | 75054 | 2.89E + 05 | 1.13E +06 | 71.077 | 0.207 | 0.928 |
Diagnosis combined effect | antagonism | antagonism | antagonism | Â | Â | Â |
NCI-N87 | Combination Index value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
5-FU | Â | Â | Â | 119.61 | 0.25 | 0.97 |
HER |  |  |  | 1.1E + 05 | 0.19 | 0.63 |
5-FU + HER | 1.9E + 17 | 3.2E + 02 | 5.3E +29 | 3.7E + 14 | −0.02 | 0.87 |
Diagnosis combined effect | antagonism | antagonism | antagonism | Â | Â | Â |
U-87 MG | Combination Index value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
5-FU | Â | Â | Â | 46.58 | 0.4 | 0.84 |
HER | Â | Â | Â | 1845.53 | 0.46 | 0.86 |
5-FU + HER | 25540 | 4940.8 | 955.81 | 6.48 | 0.98 | 1 |
Diagnosis combined effect | antagonism | antagonism | antagonism | Â | Â | Â |
SK-BR-3 | Combination Index value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
5-FU | Â | Â | Â | 753.42 | 0.52 | 0.93 |
HER |  |  |  | 1.42E + 06 | 0.05 | 0.43 |
5-FU + HER | 226.52 | 173.36 | 132.68 | 488.15 | 0.6 | 0.93 |
Diagnosis combined effect | antagonism | antagonism | antagonism | Â | Â | Â |